Compare Inovio Pharmaceuticals Inc (INO) vs Toronto-Dominion Bank (TD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Toronto-Dominion Bank — how do they compare? Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M), while Toronto-Dominion Bank trades at $123.04 (market cap $200.48B). The key difference: Toronto-Dominion Bank is far larger — about 2552.3× Inovio Pharmaceuticals Inc's market cap, and Toronto-Dominion Bank pays a 2.63% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | TD | |
|---|---|---|
Market Cap | $78.55M | $200.48B |
Sector | Health | Financials |
52-Week High | $2.87 | $124.80 |
52-Week Low | $0.66 | $72.85 |
Enterprise Value | $49.56M | — |
Dividend Yield | — | 2.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $0.76, up 2.74% today, but remains in a bearish technical trend. The company shows minimal revenue of $65K against high operating losses, with a net income margin of -130,000%. Recent quarterly EPS has beaten expectations. Analyst consensus is bullish with a $3.25 price target, but the stock faces significant fundamental challenges including negative cash flow and high valuation multiples.
The outlook hinges on FDA approval of INO-3107 in October 2026, a binary event that could drive substantial upside. However, persistent cash burn, negative profitability, and ongoing shareholder litigation present high risks. Investors should weigh the potential catalyst against the company's weak financial health and operational execution challenges.
TD stock trades at $123.01, up 1.59% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported strong 2025 results with $61.28B revenue and $20.54B net income, though cash flow from operations was negative. Analyst consensus is positive with 9 buy ratings and no sell recommendations. Recent news highlights TD Auto Finance's industry recognition and AI-driven operational efficiencies.
The outlook is favorable given earnings momentum and dividend stability, but risks include volatile operating cash flows and high debt levels. Valuation metrics like P/E of 19.88 and P/B of 2.48 suggest reasonable pricing relative to peers, supporting a cautiously optimistic view for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Toronto-Dominion Bank
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →
